All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study

Cancer Medicine

Volumn 8, Issue 13, 2019, Pages 6127-6138

  Heijnsdijk, Eveline A M ^a   Csanádi, Marcell ^b   Gini, Andrea ^a   ten Haaf, Kevin ^a   Bendes, Rita ^b   Anttila, Ahti ^c   Senore, Carlo ^d   de Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Syreon Research Institute   (Hungary)

^c FINNISH CANCER REGISTRY   (Finland)

^d CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

breast; cancer screening; colorectal; evaluation; lung; mortality reduction; trial

Indexed keywords

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; COLORECTAL CANCER; EARLY DIAGNOSIS; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; INCIDENCE; LUNG CANCER; MAMMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SIGMOIDOSCOPY; SIMULATION; SURVIVAL RATE; SYSTEMATIC REVIEW; BREAST TUMOR; CAUSE OF DEATH; COLORECTAL TUMOR; EARLY CANCER DIAGNOSIS; LUNG TUMOR; MASS SCREENING; MORTALITY; THEORETICAL MODEL;

BREAST NEOPLASMS; CAUSE OF DEATH; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; MASS SCREENING; MODELS, THEORETICAL;

EID: 85070840398     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.2476     Document Type: Article

References (42)

1. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 2002;94(3):167-173.
2. Interventions IWGotEoC-P, ed. Breast cancer screening. Lyon: International Agency for Research on Cancer;. 2016.
3. Gøtzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;6:CD001877.
4. Penston J. Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? Yes. BMJ. 2011;343:d6395.
5. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205-2240.
6. Steele RJ, Brewster DH. Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? No. BMJ. 2011;343:d6397.
7. Tabar L, Duffy SW, Yen M-F, et al. All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. J Med Screen. 2002;9(4):159-162.
8. Weiss NS. All-cause mortality as an outcome in epidemiologic studies: proceed with caution. Eur J Epidemiol. 2014;29(3):147-149.
9. Stang A, Jockel KH. The impact of cancer screening on all-cause mortality. Dtsch Arztebl Int. 2018;115(29–30):481-486.
10. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720.
11. Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2016;315(23):2576-2594.
12. Newman DH. Screening for breast and prostate cancers: moving toward transparency. J Natl Cancer Inst. 2010;102(14):1008-1011.
13. National Lung Screening Trial Research T, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
14. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909-919.
15. Tabar L, Vitak B, Chen HH, et al. The Swedish two-county trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin N Am. 2000;38(4):625-651.
16. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027-2035.
17. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624-1633.
18. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25):2345-2357.
19. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2012;61(7):1036-1040.
20. Swartz AW, Eberth JM, Josey MJ, Strayer SM. Re-analysis of all-cause mortality in the U.S. preventive services task force 2016 evidence report on colorectal cancer screening. Ann Int Med. 2017;167(8):602-603.
21. Pinsky PF, Miller EA, Zhu CS, Prorok PC. Overall mortality in men and women in the randomized prostate, lung, colorectal, and ovarian cancer screening trial. J Med Screen. 2019;969141319839097.
22. Hanley JA. Measuring mortality reductions in cancer screening trials. Epidemiol Rev. 2011;33:36-45.
23. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the prostate, lung, colorectal, and ovarian (PLCO) randomized trial. JAMA. 2011;306(17):1865-1873.
24. ten Haaf K, van Rosmalen J, de Koning HJ. Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. Cancer Epidemiol Biomark Prev. 2015;24(1):154-161.
25. de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst. 1995;87(16):1217-1223.
26. Bjurstam N, Björneld L, Warwick J, et al. The Gothenburg breast screening trial. Cancer. 2003;97(10):2387-2396.
27. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
28. Sankatsing VD, Heijnsdijk EA, van Luijt PA, van Ravesteyn NT, Fracheboud J, de Koning HJ. Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands. Int J Cancer. 2015;137(8):1990-1999.
29. Arminski TC, McLean DW. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum. 1964;7:249-261.
30. Clark JC, Collan Y, Eide TJ, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer. 1985;36(2):179-186.
31. van der Meulen MP, Lansdorp-Vogelaar I, van Heijningen EM, Kuipers EJ, van Ballegooijen M. Nonbleeding adenomas: evidence of systematic false-negative fecal immunochemical test results and their implications for screening effectiveness-A modeling study. Cancer. 2016;122(11):1680-1688.
32. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer. 2009;115(11):2410-2419.
33. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine. 2009;6(7):e1000100.
34. Carreras G, Gorini G, Paci E. Can a national lung cancer screening program in combination with smoking cessation policies cause an early decrease in tobacco deaths in Italy? Cancer Prev Res. 2012;5(6):874-882.
35. Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Lung Cancer. 2005;48(2):171-185.
36. McMahon PM, Kong CY, Johnson BE, et al. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology. 2008;248(1):278-287.
37. Marshall T. Informed consent for mammography screening: modelling the risks and benefits for American women. Health Expect. 2005;8(4):295-305.
38. Pharoah P, Sewell B, Fitzsimmons D, Bennett HS, Pashayan N. Cost effectiveness of the NHS breast screening programme: life table model. BMJ. 2013;346:f2618.
39. Sigurdsson JA, Getz L, Sjonell G, Vainiomaki P, Brodersen J. Marginal public health gain of screening for colorectal cancer: modelling study, based on WHO and national databases in the Nordic countries. J Eval Clin Pract. 2013;19(2):400-407.
40. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax. 2012;67(4):296-301.
41. Bretthauer M, Kalager M. Principles, effectiveness and caveats in screening for cancer. Br J Surg. 2013;100(1):55-65.
42. Erpeldinger S, Fayolle L, Boussageon R, et al. Is there excess mortality in women screened with mammography: a meta-analysis of non-breast cancer mortality. Trials. 2013;14:368.